Page 29 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

Breast cancer survivor meeting set for Feb. 10

The Wabash Valley Breast Cancer Survivor Organization at 10:30 a.m. Feb. 10 in the MCL Cafeteria (private side room) at the Meadows Shopping Center. ....

Edward Jones , Mark Metheney , Wabash Valley Breast Cancer Survivor Organization , Meadows Shopping Center , Meadows Shopping ,

Obesity linked to 73% higher risk of precursor to blood cancer | NEWS.am Medicine

While significant advancements have been made in therapeutics for multiple myeloma. ....

United States , Centers For Disease , American Medical Association , Disease Control , Book Compilation , News Am Health , Armenian Medicine , Healthy Life , Women Health , Men Health , Child Health , Medicine Of Future , Sexual Life , Infectious Diseases , Healthcare Policy ,

Dr Kirollos Hanna Talks Chemotherapy Shortage Challenges and Solutions

Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway. ....

United States , Kirolloss Hanna , Minnesota Oncology , American Journal , Managed Care ,

Huntsville's Clearview Cancer Institute Announces Partnership With OneOncology

OneOncology and Clearview Cancer Institute of Huntsville finalized a new partnership for the delivery of cancer care services throughout Alabama. ....

United States , Marshall Schreeder , John Waples , Jeff Patton , Gary Walton , Huntsville Clearview Cancer Institute , Clearview Cancer Institute , North Alabama , Cancer Care , Community Care ,

Prolonged rituximab maintenance therapy does not provide overall survival benefit in low-burden follicular lymphoma

1. In patients with low tumor burden follicular lymphoma (LTBFL): Rituximab maintenance therapy does not improve overall survival in comparison to retreatment at 10 year follow-up. 2. Rituximab maintenance therapy is superior to retreatment therapy for freedom of cytotoxic therapy and response duration at 7-year follow-up. Evidence Rating Level: 1 Study Rundown: The RESORT study ....

Rating Level , Follicular Lymphoma , Low Tumor Burden Follicular Lymphoma , Chronic Disease ,